Published in Dis Model Mech on March 09, 2010
AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene (2013) 1.27
The cellular architecture of multiple myeloma. Cell Cycle (2012) 0.85
MALT lymphoma meets stem cells. Cell Cycle (2012) 0.80
TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality. Sci Rep (2015) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (1986) 14.56
Crypt stem cells as the cells-of-origin of intestinal cancer. Nature (2008) 11.66
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature (2001) 10.56
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 9.78
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47
The case for early detection. Nat Rev Cancer (2003) 6.96
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell (1984) 6.71
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Oct4-induced pluripotency in adult neural stem cells. Cell (2009) 6.50
A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature (2009) 5.65
Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature (2008) 5.59
Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature (2007) 5.39
Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet (2009) 4.28
Cancer stem cells in solid tumors. Curr Opin Biotechnol (2007) 3.91
Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell (1986) 3.70
Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet (2000) 3.67
An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell (1996) 3.60
Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet (1997) 2.64
A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood (2000) 2.42
Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Res (2003) 2.28
Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell (2004) 2.08
The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet (1999) 2.02
Dre recombinase, like Cre, is a highly efficient site-specific recombinase in E. coli, mammalian cells and mice. Dis Model Mech (2009) 1.97
Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature (2009) 1.89
The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J (1999) 1.88
The cancer stem cell hypothesis: a work in progress. Lab Invest (2006) 1.87
Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell (1996) 1.84
Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell (2003) 1.79
SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum Mol Genet (2002) 1.64
Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J (2008) 1.52
Stem-cell driven cancer: "hands-off" regulation of cancer development. Cell Cycle (2009) 1.10
The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice? Bioessays (2007) 1.10
Normal and neoplastic stem cells. Novartis Found Symp (2005) 1.04
Human beta-globin gene sequences injected into mouse eggs, retained in adults, and transmitted to progeny. Science (1982) 1.01
Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice. Oncogene (2006) 0.93
The Emerging Picture of Human Breast Cancer as a Stem Cell-based Disease. Stem Cell Rev (2008) 0.82
Precancerous lesions upon sporadic activation of beta-catenin in mice. Gastroenterology (2007) 0.79
Factors influencing laboratory animal spontaneous tumor profiles. Toxicol Pathol (1985) 0.76
Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity (2008) 2.11
Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol (2009) 2.05
Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature (2009) 1.89
TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer (2010) 1.73
Deletion of the SLUG (SNAI2) gene results in human piebaldism. Am J Med Genet A (2003) 1.72
Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood (2002) 1.64
SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum Mol Genet (2002) 1.64
Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J (2008) 1.52
Function of the zinc-finger transcription factor SNAI2 in cancer and development. Annu Rev Genet (2007) 1.46
SLUG in cancer development. Oncogene (2005) 1.42
The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug. Oncogene (2003) 1.26
B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. Bioessays (2009) 1.24
Immortalized mouse mammary fibroblasts lacking dioxin receptor have impaired tumorigenicity in a subcutaneous mouse xenograft model. J Biol Chem (2005) 1.19
Cancer development induced by graded expression of Snail in mice. Hum Mol Genet (2005) 1.18
Snail family transcription factors are implicated in thyroid carcinogenesis. Am J Pathol (2007) 1.17
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J (2012) 1.12
Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci U S A (2013) 1.11
Stem-cell driven cancer: "hands-off" regulation of cancer development. Cell Cycle (2009) 1.10
The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice? Bioessays (2007) 1.10
Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biol (2011) 1.08
Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice. Oncotarget (2012) 1.07
Mouse cDNA microarray analysis uncovers Slug targets in mouse embryonic fibroblasts. Genomics (2005) 1.05
The age of the target cell affects B-cell leukaemia malignancy. Aging (Albany NY) (2010) 1.04
Cancer as a reprogramming-like disease: implications in tumor development and treatment. Semin Cancer Biol (2010) 1.03
Function of oncogenes in cancer development: a changing paradigm. EMBO J (2013) 1.02
FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. PLoS One (2008) 0.99
Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nat Commun (2013) 0.98
C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics (2013) 0.98
HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway. Blood (2010) 0.97
Adipose tissue mass is modulated by SLUG (SNAI2). Hum Mol Genet (2007) 0.95
Killing time for cancer stem cells (CSC): discovery and development of selective CSC inhibitors. Curr Med Chem (2006) 0.92
Getting to the stem of cancer. Semin Cancer Biol (2010) 0.91
Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood (2012) 0.90
Bcl2 is not required for the development and maintenance of leukemia stem cells in mice. Carcinogenesis (2010) 0.89
Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB. Cell Cycle (2012) 0.87
The cellular architecture of multiple myeloma. Cell Cycle (2012) 0.85
Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development. Carcinogenesis (2007) 0.84
The Emerging Picture of Human Breast Cancer as a Stem Cell-based Disease. Stem Cell Rev (2008) 0.82
Aspects of antioxidant foods and supplements in health and disease. Nutr Rev (2009) 0.81
p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice. Cell Cycle (2012) 0.81
Breast cancer, a stem cell disease. Curr Stem Cell Res Ther (2008) 0.80
MALT lymphoma meets stem cells. Cell Cycle (2012) 0.80
Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice. Oncogene (2002) 0.80
Acute lymphoblastic leukemia and developmental biology: a crucial interrelationship. Cell Cycle (2011) 0.79
Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach. Genome Biol (2015) 0.78
Understanding telomerase in cancer stem cell biology. Cell Cycle (2012) 0.78
Back to the beginning: The initiation of cancer. Bioessays (2013) 0.78
Genetic background affects susceptibility to tumoral stem cell reprogramming. Cell Cycle (2013) 0.78
Identifying phenotypes involved in susceptibility to Schistosoma mansoni infection in F1B6CBA mice. Acta Parasitol (2014) 0.76
Genetically engineered mouse models of human B-cell precursor leukemias. Cell Cycle (2014) 0.76
Early epigenetic cancer decisions. Biol Chem (2014) 0.76
Schistosoma mansoni experimental infection in Mus spretus (SPRET/EiJ strain) mice. Parasite (2013) 0.75
Stem cell aging and cancer: immortal but vulnerable. Cell Cycle (2011) 0.75
Medical chemistry to spy cancer stem cells from outside the body. Mini Rev Med Chem (2007) 0.75
New models towards assessing anti-cancer therapeutics. Histol Histopathol (2012) 0.75